Loading...
XNAS
KYNB
Market cap29mUSD
Jul 09, Last price  
7.32USD
1D
-2.27%
1Q
2.09%
Jan 2017
-65.79%
IPO
-69.26%
Name

FibroGen Inc

Chart & Performance

D1W1MN
XNAS:KYNB chart
P/E
0.16
P/S
4.60
EPS
45.35
Div Yield, %
—
Shrs. gr., 5y
-46.22%
Rev. gr., 5y
-48.42%
Revenues
6m
-78.26%
65,933,000102,170,000137,601,000180,828,000179,577,000125,668,000212,958,000256,577,000176,319,000235,309,000140,734,00046,803,00029,621,0006,440,000
Net income
183m
P
-32,571,000-14,943,000-59,504,000-85,779,000-61,680,000-126,203,000-86,420,000-76,970,000-189,291,000-290,023,000-293,654,000-284,232,000-47,579,000183,452,000
CFO
-5m
L-96.54%
-5,605,00025,918,00022,414,000-18,571,0007,108,000-66,513,000-76,144,000-78,705,00081,602,000-82,232,000-145,933,000-315,021,000-137,999,000-4,774,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
URL
https://www.fibrogen.com/
IPO date
Nov 14, 2014
Employees
592
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT